Pulmonary Fibrosis News and Research

RSS

What are the risk factors associated with post-acute SARS-CoV-2 infection?

In a recent study posted to the Research Square* preprint server, researchers assessed the risk factors and predictive models for post-acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

13 Mar 2023

Study: Black patients with pulmonary fibrosis are younger than Hispanic and white counterparts

Pulmonary fibrosis is a devastating disease characterized by progressive scarring in the lungs, killing up to half of patients within five years of a diagnosis.

10 Mar 2023

ACE2: its diverse functions, relationship with SARS-CoV-2, and the implications for COVID-19 disease sequelae

Researchers assessed the role of ACE2 in the COVID-19 pandemic.

9 Mar 2023

Study identifies the essential genetic and immunologic perturbations occurring in patients with long COVID lung fibrosis

Researchers elucidated immunologic and genetic perturbations in long COVID patients with pulmonary fibrosis.

3 Mar 2023

Study reveals synergistic impact of estrogen and intestinal dysbiosis on pulmonary fibrosis

In a recent study published in Cells, researchers evaluated idiopathic pulmonary fibrosis (IPF) pathophysiological differences by sex and intestinal microbiome.

1 Mar 2023

New clinician toolkit aims to close the gaps in diagnosis of interstitial lung diseases

The expert steering committee for Bridging Specialties: Timely Diagnosis for ILD is encouraging primary care and pulmonary clinicians to come together on Rare Disease Day (February 28) to explore ways to shorten the time to diagnosis for pulmonary fibrosis and other interstitial lung diseases.

28 Feb 2023

The impact of specific comorbidities and overall multimorbidity on the three mechanistically distinct phases of COVID-19

Researchers studied the impact of comorbidities in the three distinct phases of COVID-19.

21 Feb 2023

Chest CT reveals persistent lung abnormalities in patients two years post-COVID

Chest CT revealed persistent lung abnormalities in patients two years after COVID-19, according to a study published in Radiology, a journal of the Radiological Society of North America.

14 Feb 2023

Researchers report a physical barrier against SARS-CoV-2 infection based on an inhalable bioadhesive hydrogel

Researchers developed spherical hydrogel inhalation for enhanced lung defense to protect against SARS-CoV-2 infections.

13 Feb 2023

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

University of Sydney scientists have discovered a protein in the lung that blocks SARS-CoV-2 infection and forms a natural protective barrier in the human body.

9 Feb 2023

A review of innate immunity relevant to SARS-CoV-2 and COVID-19

In a recent study published in The New England Journal of Medicine, researchers reviewed selected acute-phase proteins concerning their production, structure, and function.

7 Feb 2023

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.

23 Jan 2023

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Researchers have designed the first 'living medicine' to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.

19 Jan 2023

Could drinking tea help manage COVID-19?

Researchers summarized the content of active ingredients in different types of tea, the second most consumed beverage in the world. They also explored the possibility of using tea extracts for coronavirus disease 2019 (COVID-19) prevention and treatment.

17 Jan 2023

Understanding the molecular basis of how THC cannabinoid inhibits an important human enzyme

In various European countries and North America, medical cannabis or medicines based on cannabinoids are authorized for therapeutic purposes.

9 Jan 2023

Comprehensive lung cell atlas offers insights into an unexpected immune niche in the airways

The most comprehensive lung cell atlas to date, from the Wellcome Sanger Institute and collaborators, has revealed 11 new lung cell types and offers detailed insight into an immune process involved in fighting lung infections.

21 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

What is the prevalence of pulmonary tissue injury among hospitalized COVID-19 patients?

Researchers identified risk factors for and the prevalence of persistent pulmonary tissue alterations among hospitalized coronavirus disease 2019 (COVID-19) patients.

7 Dec 2022

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Researchers evaluated compositional and structural pulmonary alterations in PASC tissues.

5 Dec 2022

Collaborative work unravels hidden molecular secrets of age-related diseases

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release of the first batch of results from the collaborative work directed to perform multi-omics-based analyses in the context of age-related diseases using an AI-driven target and drug discovery pipeline.

2 Dec 2022